

# Interim report

January-June 2024



# The first half in review

## Jan – Jun 2024

- Net sales decreased 41% to 13,0 MSEK (22,1) with. Sales in North America has been weak during the first half, while European sales have been somewhat stronger. We are looking forward to stronger sales in the second half, as a result of increased order intake.
- Order intake increased by 16% to 18,3 MSEK (15,9).
- Net profit for the first half was -18,9 MSEK (-28,8). The improvement can be explained by the cost reduction program, improved gross margins and lower OPEX.
- Earnings per share in the first half of the year amounted to -0,49 SEK (-0,81).
- Cash flow from operating activities amounted to -22,7 MSEK (-26,4).
- Bank deposits amounted to 16,7 MSEK (43,0) at the end of the period.

## Significant events during the first half

- Bio-Works received a new order from a production customer in the Netherlands worth 2.4 MSEK. The customer is a global manufacturer of active pharmaceutical ingredients (APIs) with approximately 1,800 employees.
- Bio-Works received a second order from the production customer in the Netherlands worth 2.4 MSEK.
- Bio-Works confirmed a production-scale order worth 3.1 MSEK to an Indian manufacturer of bio-therapeutics. This order is a repeat order from a customer which first started using Bio-Works' products in 2021.
- Bio-Works Technologies AB has been subjected to a tax surcharge of 2.0 MSEK following a decision by the Swedish Tax Agency.
- The Court of Appeals verdict on March 25, 2024, has been appealed to the Supreme Administrative Court.
- Bio-Works confirmed yet another order from production customer in the Netherlands who placed two orders earlier this year. The latest order is worth SEK 2.9 million.
- Lone Carlbom has assumed the role of CEO of Bio-Works from the 15. of May. The company's CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works' Board of Directors, effective immediately (all one-off costs are included in the Q2 results).
- Bio-Works has received another order from a production customer in India. The customer is a manufacturer of bio-therapeutics. The order is worth SEK 2.6 million.
- Bio-Works Technologies and Amicogen Inc. of South Korea have concluded their mutual technology transfer project allowing Amicogen to establish local production of agarose resins in South Korea. As a result, Bio-Works and Amicogen have settled outstanding payables from Bio-Works with outstanding receivables from Amicogen.

- Bio-Works Technologies resolves on fully secured rights issue of approximately SEK 39 million and announces intention to change listing venue to Spotlight Stock Market. The rights issue has been guaranteed by Bio-Works major shareholders without remuneration or compensation.
- Notice Extra General Meeting Bio-Works Technologies AB Monday the 29. of July 2024 at 11:00.

## Significant events after the period end

- Bio-Works Technologies AB has been approved for listing on the Spotlight Stock Market. Bio-Works' stock has been listed on Spotlight Stock Market since the 18. of July where it is traded under the ticker BLOWKS. The ISIN code for the stock is SE0007387089.

## Message from the CEO

As we review the first half of the year, I am pleased to report that Bio-Works is showing strong signs of recovery following a challenging 2023. Our order intake has increased by 16% compared to the same period last year, reaching a total of 18.3 MSEK. This robust growth in orders sets a promising outlook for the second half of the year.

A significant portion of our growth is driven by large volume orders for our ion exchange and affinity resins. This indicates that our customers are scaling up their operations, presenting a significant opportunity for repeated sales and long-term partnerships for Bio-Works.

We are also excited to announce that as of July 1st, Anne Dyrdal has joined us as the Director of Global Sales. Ms. Dyrdal has 25 years of experience from sales positions at Waters, Sciex, Shimadzu and GE Healthcare (Cytiva). Her expertise will enhance our sales planning and execution, resulting in a more efficient and successful sales organization.

In addition to bolstering our sales efforts, we are diligently executing our cost-saving program as previously communicated. Our projected goal to reduce operating costs by 24 MSEK during 2024 remains still valid and will, of course, be realized. This initiative is crucial for improving our financial health and supporting sustainable growth.

Reflecting upon my first eight weeks as CEO, I am profoundly impressed by the strong relationships we have built with our customers. Our interactions are open and based on trust, and the feedback we receive highlights our responsiveness and diligent technical support.

I am equally impressed by our talented employees, whose expertise and dedication have been fundamental to Bio-Works' development. Their hard work continues to drive our progress, and I am confident that we have the depth of proficiency needed to achieve absolute success in the near future.

Lastly, I am particularly proud of the quality of our products. Our ion exchangers, for instance, are top of the class in purifying oligonucleotides and peptides. As clinical projects involving peptides and oligonucleotides increase, Bio-Works is well-positioned to provide our customers with the tools they need to produce therapies with higher yields and purity at lower production costs.

In conclusion, we have a strong technical foundation to build upon. By continuing to improve our commercialization efforts and maintaining strict cost control, I believe the potential for Bio-Works is immense.

I am honored to lead this exceptional team and deeply grateful to our shareholders for their support, demonstrated not the least with Bio-Works' upcoming fully secured Rights issue, through their subscription commitments and the free of charge guarantee commitments of our largest shareholders. This token of trust is, of course, something that Bio-Works will manage with the outmost concern and deliver excellent results on.

Lone Carlbom  
Chief Executive Officer  
Bio-Works Technologies AB



# The Group

<b>BIO-WORKS GROUP KEY PERFORMANCE INDICATORS</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amount in KSEK	<b>jan-jun</b>	<b>jan-jun</b>	<b>jan-dec</b>
Net sales	13 014	22 068	43 896
Order intake	18 346	15 881	26 085
<b>Operating profit/loss</b>	-19 155	-29 745	-56 348
<b>Profit/loss for the period</b>	-18 912	-28 777	-56 821
Cash flow from operating activities	-22 737	-26 427	-58 990
Bank balance	16 683	42 971	39 382
Equity	25 171	42 635	44 033
Equity ratio (%)	71%	65%	71%

  

	<b>2024</b>	<b>2023</b>	<b>2023</b>
<b>Earnings per share (SEK)</b>	<b>jan-jun</b>	<b>jan-jun</b>	<b>jan-dec</b>
Share price per closing day	2,45	12,9	7,1
Earnings per share	-0,49	-0,81	-1,62

  

	<b>2024</b>	<b>2023</b>	<b>2023</b>
<b>Number of shares</b>	<b>jan-jun</b>	<b>jan-jun</b>	<b>jan-dec</b>
Number of shares period start	38 979 790	35 162 146	35 162 146
Number of shares period end	38 979 790	35 462 146	38 979 790
Average number of shares	38 979 790	35 162 146	36 113 273

## The group's development during the period

### Orders received

Bio-Works' order intake increased by 16% to 18,3 MSEK in the first half of 2024 compared to 15,9 MSEK in the same period in the previous year. We see the increase in orders received as an indication that customer sentiment is improving after a tough 2023.

### Net sales

Net sales decreased in the first half of 2024 by 41% compared to the previous year and amounted to 13,0 MSEK (22,1). Sales in North America has continued to be weak under the first half, while Europe has been somewhat stronger. Lower sales in Asia due to unregular order pattern from Bio-Works largest customer in the region. We are looking forward to a general improvement in sales in the second half.

	2024	2023	2023
NET SALES	Jan-Jun	Jan-Jun	Full year
Europe	9 837	12 716	31 665
North America	3 034	8 872	11 293
Asia	143	480	939
<b>Total</b>	<b>13 014</b>	<b>22 068</b>	<b>43 896</b>

## Earnings

Other operating income was 5,9 (0,4) MSEK in the first half. This is explained by one-off revenues from the conclusion of Bio-Works Technologies and Amicogen Inc. of South Korea mutual technology transfer project allowing Amicogen to establish local production of agarose resins in South Korea. Bio-Works and Amicogen have settled outstanding payables from Bio-Works with outstanding receivables from Amicogen.

Profit for the first half of 2024 amounted to -18,9 (-28,8) MSEK. The improvement can be explained by the cost reduction program, improved gross margins and lower OPEX.

Personnel costs amounted to 22,6 (23,7) MSEK for the period. Personnel costs are impacted negatively by one-off costs related to personnel reductions. One-off items were -3,0 MSEK in the first half (all one-off costs from organizational changes are included in personnel costs in the Q2 results). We are expecting significantly lower personnel costs in the second half. At the end of the period the number of employees were 33 compared with 48 one year ago.

The cost of raw materials and other supplies decreased by 6,6 MSEK to 2,1 (8,7) MSEK, which is explained by a different product mix compared with the same period last year.

The other external costs amounted to 12,6 (18,9) MSEK. The reduction can be explained by the cost reduction program initiated last year, lower costs for consultants, a down-sized marketing department and other OPEX reduction initiatives.

Depreciation in the first half of 2024 was 0.3 (0,3) MSEK.

Operating profit in the first half of 2024 amounted to -19,2 (-29,7) MSEK compared to the first half of 2023. The improvement can be explained by the cost reduction program under the second half of 2023 and the first half of 2024. We expect an improvement in operating profit in the second half, with lower personnel costs and increased sales revenues.

The total booked tax for the first half of 2024 was -0.1 (-0,1) MSEK.

Net financial items for the period amounted to 0,3 (1,1) MSEK, mostly related to exchange rate effects which amounted to 0,1 (0,9) MSEK.

## Financing and cash flow

Cash flow from operating activities was -22,7 (-26,4) MSEK, and cash flow from investment activities amounted to 0,0 (-0,2) MSEK. Cash flow from financing activities was -0,1 (3,7) MSEK.

Cash flow for the period amounted to -22,8 (-22,9) MSEK.

Cash and cash equivalents at the end of the period were 16,7 (43,0) MSEK and 39,4 MSEK December 31, 2023.

It is the company's assessment that the company's operations are financed for at least the next 12 months, given the fully guaranteed rights issue.

Bio-Works Technologies AB has been subjected to a tax surcharge of 2.0 MSEK following a decision by the Swedish Tax Agency. The Court of Appeals verdict on March 25, 2024, has been appealed to the Supreme Administrative Court. The company's stance is that the tax surcharge is disproportionate in relation to the single mistake made in the tax filing. Since there is an element of uncertainty in the appeal process to the Supreme Administrative Court, the company decided to book the tax surcharge to costs in the Annual Report for 2023.

## The share & shareholders

Bio-Works' stock has been listed on Spotlight Stock Market since the 18. of July where it is traded under the ticker BLOWKS. The ISIN code for the stock is SE0007387089.

Number of shares December 31, 2023 38 979 790

Number of shares Juni 30, 2024 38 979 790

On June 30, 2024, Bio-Works Technologies AB had 2 262 shareholders (2 397 on December 31, 2023).

Shareholder	Number of shares	Share of votes
SWEDIA INVEST AB	7 326 021	18,8%
CALYPTRA AB	6 125 724	15,7%
RHENMAN & PARTNERS VIA SKANDINAVISKA ENSKILDA BANKEN /	1 502 014	3,9%
AVANZA PENSION	1 398 575	3,6%
FÄRJSUNDET INDUSTRI AKTIEBOLAG / PETER EHRENHEIM	1 284 323	3,3%
DARIUSH HOSSEINIAN	1 247 184	3,2%
BONIT INVEST AB	982 588	2,5%
FUTURPENSION	779 496	2,0%
MALMGREN, OLOF MATHIAS	730 000	1,9%
NORDNET PENSIONS FÖRSÄKRING AB	640 109	1,6%
<b>The ten largest shareholders</b>	<b>22 016 034</b>	<b>56,5%</b>
Other shareholders	16 963 756	43,5%
<b>Totals</b>	<b>38 979 790</b>	<b>100,0%</b>

On June 30, 2024, 123,000 warrants remained outstanding per the table below.

Series	Typ	Teckningsperiod	Optionspris (SEK)	Teckningskurs (SEK)	Optioner	Aktiekapital-ökning	Antal aktier
2023/2026	Personal	2023-05-26 – 2026-06-30	2,94	18,56	123 000	12 300	123 000

## Employees

The group's average number of employees during the first half of the year was 34,8 (50,2) and full-time employees were 32,3 (43,9). At the end of June, the number of employees was 33 (48).



## Accounting and valuation principles

Annual accounts and interim reports are prepared in accordance with the Swedish Annual Accounts Act and BFNAR 2012: 1 (K3). The rules applied are unchanged compared to the previous year.



# Financial reports

## Group

<b>GROUP INCOME STATEMENT</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amounts in KSEK	jan-juni	jan-juni	jan-dec
<b>OPERATING INCOME</b>			
Net sales	13 014	22 068	43 896
Change in inventory	278	240	1 384
Other operating income	5 918	446	1 424
<b>TOTAL OPERATING INCOME</b>	<b>19 210</b>	<b>22 754</b>	<b>46 704</b>
<b>OPERATING EXPENSES</b>			
Raw materials and consumables	-2 108	-8 704	-18 459
Other external expenses	-12 598	-18 947	-35 976
Personnel costs	-22 580	-23 663	-45 651
Depreciation of assets	-259	-302	-611
Other operating costs	-819	-882	-2 355
<b>TOTAL OPERATING EXPENSES</b>	<b>-38 365</b>	<b>-52 498</b>	<b>-103 052</b>
<b>OPERATING PROFIT / LOSS</b>	<b>-19 155</b>	<b>-29 745</b>	<b>-56 348</b>
<b>INTEREST INCOME, EXPENSE AND SIMILAR ITEMS</b>			
Interest earnings and similar sources of income	484	1 077	1 617
Interest costs and similar expenses	-153	-2	-3
<b>TOTAL INTEREST INCOME, EXPENSE AND SIMILAR ITEMS</b>	<b>331</b>	<b>1 075</b>	<b>1 614</b>
<b>PROFIT / LOSS BEFORE TAX</b>	<b>-18 824</b>	<b>-28 670</b>	<b>-54 734</b>
Income tax	-88	-107	-2 087
<b>NET PROFIT / LOSS</b>	<b>-18 912</b>	<b>-28 777</b>	<b>-56 821</b>
<b>EARNINGS PER SHARE (before / after dilution)</b>	<b>-0,49</b>	<b>-0,81</b>	<b>-1,62</b>

<b>BIO-WORKS GROUP BALANCE SHEET</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amount in KSEK	<b>30-Jun</b>	<b>30-Jun</b>	<b>31-Dec</b>
<b>ASSETS</b>			
<b>Fixed assets</b>			
Tangible fixed assets	2 072	2 329	2 489
<b>Total fixed assets</b>	<b>2 072</b>	<b>2 329</b>	<b>2 489</b>
<b>Current assets</b>			
Inventory	10 298	11 781	9 068
Accounts receivable	1 480	4 052	7 151
Other short-term receivables	1 318	1 229	1 183
Prepaid expenses and accrued income	3 490	3 403	2 879
Cash and bank balances	16 683	42 971	39 382
<b>Total current assets</b>	<b>33 270</b>	<b>63 435</b>	<b>59 663</b>
<b>TOTAL ASSETS</b>	<b>35 342</b>	<b>65 764</b>	<b>62 152</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital	3 898	3 546	3 898
Other contributed capital	345 823	316 679	345 893
Other equity incl. profit for the period	-324 550	-277 591	-305 758
<b>Total equity</b>	<b>25 171</b>	<b>42 635</b>	<b>44 033</b>
<b>Short-term liabilities</b>			
Accounts payable	1 367	9 417	8 325
Customer prepayments	275	6 748	173
Tax liabilities	0	0	2 244
Other short-term liabilities	2 647	1 951	2 005
Accrued expenses and deferred incomes	5 882	5 013	5 372
<b>Total liabilities</b>	<b>10 170</b>	<b>23 128</b>	<b>18 119</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>35 342</b>	<b>65 764</b>	<b>62 152</b>

<b>GROUP CASH FLOW STATEMENT</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amounts in KSEK	jan-juni	jan-jun	jan-dec
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Operating profit / loss	-19 155	-29 745	-56 348
<b>Adjustments to cash flow from operating activities:</b>			
Depreciation and amortization	429	302	611
Currency effects	76	905	0
Interest received	408	172	1 617
Interest paid	-153	-2	-3
Taxes	-88	-107	-2 087
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
<b>BEFORE WORKING CAPITAL CHANGES</b>	<b>-18 483</b>	<b>-28 475</b>	<b>-56 210</b>
<b>WORKING CAPITAL CHANGES</b>			
Increase (-)/Decrease (+) in inventory	-1 230	-2 108	605
Increase (-)/Decrease (+) in operating receivables	4 925	4 949	2 419
Increase (-)/Decrease (+) in operating liabilities	-7 949	-792	-5 804
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>-22 737</b>	<b>-26 427</b>	<b>-58 990</b>
<b>INVESTMENT ACTIVITIES</b>			
Investments in tangible assets	-8	-208	-860
<b>CASH FLOW FROM INVESTMENT ACTIVITIES</b>	<b>-8</b>	<b>-208</b>	<b>-860</b>
<b>FINANCING ACTIVITIES</b>			
New share issue, directed	0	3 390	29 900
New emission through conversion of warrants	0	0	3 390
Emission costs	-70	-57	-389
Warrant premiums	0	362	362
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>	<b>-70</b>	<b>3 695</b>	<b>33 263</b>
<b>CASH FLOW THIS PERIOD</b>			
Liquidity at the beginning of the period	39 382	65 875	65 875
Exchange rate differences	117	37	94
<b>LIQUIDITY AT THE END OF THE PERIOD</b>	<b>16 683</b>	<b>42 971</b>	<b>39 382</b>
<b>GROUP CHANGE IN EQUITY</b>			
Amounts in KSEK	jan-jun	jan-jun	jan-dec
Equity at the beginning of the period	44 033	67 691	67 691
New share issue as a result of warrant conversion	0	3 390	3 390
New share issue	0	0	29 900
Emission costs	-70	-57	-392
Warrant premiums	0	362	362
Translation differences	120	26	-97
Profit / loss for the period	-18 912	-28 777	-56 821
<b>EQUITY AT THE END OF THE PERIOD</b>	<b>25 171</b>	<b>42 635</b>	<b>44 033</b>

# Parent company

<b>PARENT COMPANY INCOME STATEMENT</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amounts in KSEK	jan-juni	jan-juni	jan-dec
<b>OPERATING INCOME</b>	<b>482</b>	<b>5 342</b>	<b>5 818</b>
<b>OPERATING EXPENSES</b>			
Other external expenses	-2 390	-3 776	-5 956
Personnel costs	-335	-3 496	-3 832
<b>TOTAL OPERATING EXPENSES</b>	<b>-2 724</b>	<b>-7 273</b>	<b>-9 788</b>
<b>OPERATING PROFIT / LOSS</b>	<b>-2 242</b>	<b>-1 930</b>	<b>-3 970</b>
<b>PROFIT / LOSS FROM FINANCIAL ITEMS</b>			
Profit / loss from associated companies	-20 541	-21 825	-40 692
Interest earnings and similar sources of income	406	167	802
Interest costs and similar expenses	-149	-1	-1
Currency effects	0	183	-43
<b>TOTAL PROFIT / LOSS FROM FINANCIAL ITEMS</b>	<b>-20 283</b>	<b>-21 476</b>	<b>-39 933</b>
<b>PROFIT / LOSS BEFORE TAX</b>	<b>-22 525</b>	<b>-23 406</b>	<b>-43 903</b>
Income tax	0	0	-2 000
<b>NET PROFIT / LOSS</b>	<b>-22 525</b>	<b>-23 406</b>	<b>-45 903</b>

<b>PARENT COMPANY BALANCE SHEET</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amounts in KSEK	<b>30-Jun</b>	<b>30-Jun</b>	<b>31-Dec</b>
<b>ASSETS</b>			
<b>Fixed assets</b>			
Financial assets	182	182	182
<b>Total fixed assets</b>	<b>182</b>	<b>182</b>	<b>182</b>
<b>Current assets</b>			
Short-term receivables with associated companies	0	103	0
Other short-term receivables	457	123	221
Prepaid expenses and accrued income	987	1149	445
<b>Total short-term assets</b>	<b>1 444</b>	<b>1 376</b>	<b>666</b>
Cash and bank balances	10 788	28 585	36 445
<b>Total current assets</b>	<b>12 232</b>	<b>29 961</b>	<b>37 111</b>
<b>TOTAL ASSETS</b>	<b>12 414</b>	<b>30 143</b>	<b>37 293</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
<b>Restricted equity</b>			
Share Capital	3 898	3 546	3 898
<b>Non-restricted equity</b>			
Other contributed capital	345 823	316 316	345 893
Retained earnings	-315 546	-269 281	-269 643
Profit/loss for the period	-22 525	-23 406	-45 903
<b>Total non-restricted equity</b>	<b>7 752</b>	<b>23 628</b>	<b>30 346</b>
<b>TOTAL EQUITY</b>	<b>11 650</b>	<b>27 174</b>	<b>34 245</b>
<b>Short-term liabilities</b>			
Accounts payable	224	1 105	265
Tax liabilities	0	0	2 000
Other short-term liabilities	335	909	0
Accrued expenses and deferred incomes	205	955	783
<b>Total short-term liabilities</b>	<b>765</b>	<b>2 969</b>	<b>3 048</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>12 414</b>	<b>30 143</b>	<b>37 293</b>

<b>PARENT COMPANY CASH FLOW STATEMENT</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amounts in KSEK	jan-juni	jan-jun	jan-dec
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Operating profit / loss	-2 242	-1 930	-3 970
<b>Adjustments to cash flow from operating activities:</b>			
Currency effects	0	183	-43
Interest received	406	167	802
Interest paid	-149	-1	-1
Tax paid	0	0	-2 000
<b>CASH FLOW FROM OPERATING ACTIVITIES BEFORE WORKING CAPITAL CHANGES</b>	<b>-1 984</b>	<b>-1 582</b>	<b>-5 212</b>
<b>WORKING CAPITAL CHANGES</b>			
Increase (-)/Decrease (+) in operating receivables	-778	-484	226
Increase (-)/Decrease (+) in operating liabilities	-2 283	-206	-2 127
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>-5 046</b>	<b>-2 272</b>	<b>-5 113</b>
<b>INVESTMENT ACTIVITIES</b>			
Shareholder contributions	-20 541	-21 825	-40 692
<b>CASH FLOW FROM INVESTMENT ACTIVITIES</b>	<b>-20 541</b>	<b>-21 825</b>	<b>-40 692</b>
<b>FINANCING ACTIVITIES</b>			
New share issue	0	3 390	33 290
Emission costs	-70	-57	-389
Warrant premiums	0	362	362
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>	<b>-70</b>	<b>3 695</b>	<b>33 263</b>
<b>CASH FLOW THIS PERIOD</b>	<b>-25 657</b>	<b>-20 402</b>	<b>-12 542</b>
Liquidity at the beginning of the period	36 445	48 987	48 987
<b>LIQUIDITY AT THE END OF THE PERIOD</b>	<b>10 788</b>	<b>28 585</b>	<b>36 445</b>

<b>PARENT COMPANY CHANGE IN EQUITY</b>	<b>2024</b>	<b>2023</b>	<b>2023</b>
Amounts in KSEK	jan-jun	jan-jun	jan-dec
Equity at the beginning of the period	34 245	46 887	46 887
New share issue as a result of warrant conversion	0	3 390	3 390
New share issue	0	0	29 900
Emission costs	-70	-57	-389
Warrant premiums	0	362	362
Profit / loss for the period	-22 525	-23 406	-45 905
<b>EQUITY AT THE END OF THE PERIOD</b>	<b>11 650</b>	<b>27 176</b>	<b>34 245</b>

# Risks

Bio-Works operations and market are subject to a number of risks which entirely or partially are out of the company's control, but which influence or may influence Bio-Works business, financial position and result. These risks are described below in no particular order and without guarantee that they are all-encompassing.

## **Business risks**

Bio-Works is in a commercialization phase which creates risks that sales revenues may vary sharply from quarter to quarter. This is due to the relatively small number of large customers who have demands which are difficult to forecast. When the number of large customers increases, this variability will decrease.

## **Environmental risks**

Bio-Works' manufacturing operations are subject to environmental controls and reporting requirements according to environmental laws which means that Bio-Works is exposed to the risk of being held responsible financially to rectify, sanify or investigate environmental issues. Bio-Works maintains a permit for handling flammable chemicals.

## **Financial risks**

It is the company's assessment that the company's operations are financed for at least the next 12 months, given the fully guaranteed rights issue.

## **Geo-political risks**

The war in the Ukraine together with geo-political tension, also in other parts of the world, has increased the level of uncertainty. Increased uncertainty has a negative impact on the world economy and global supply chains, both in the short term and in the longer term.

# The Board's declaration

The Board of Directors and the CEO assure that the interim report, to the best of their knowledge, provides a true and fair view of the Parent Company and the Group's operations, position and results and describes the most significant risks and uncertainties that the Parent Company and its subsidiaries face.

Bio-Works provides no forecasts.

Uppsala 2. of August 2024

Peter von Ehrenheim	Chairman of the board
Kirsti Gjellan	Board member
Peter Nählstedt	Board member
Thomas Gür	Board member
Jonas Ahlén	Board member
Lone Carlbom	CEO

This report has not been reviewed by the company's auditor.

This English translation is unofficial and is provided for convenience.

Financial calendar

Year-end report 2024 21. of February 2025

Q3 report 2024 6. of November 2024

All reports are available on the Bio-Works website from the specified date.

## For further information

Please visit the Bio-Works homepage at, [www.bio-works.com](http://www.bio-works.com) or contact Arne Hauge, CFO, e-mail: [info@bio-works.com](mailto:info@bio-works.com) / [arne.hauge@bio-works.com](mailto:arne.hauge@bio-works.com), phone: +46(0)8-502 705 83.